Ozurdex 0.7 mg (Dexamethasone IMPLANT) 0.7 MG

Ozurdex 0.7 mg is a dexamethasone implant used for intraocular inflammation and macular edema. This biodegradable implant delivers sustained drug release for targeted treatment.

Strength

0.7 MG

Manufacturer / TM Owner

ABBVIE CORPORATION

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Ozurdex 0.7 mg is primarily used to treat inflammation in the eye and macular edema associated with various conditions. The dexamethasone implant is designed for intraocular administration, providing localized treatment for eye-related issues. It is often considered for conditions where prolonged anti-inflammatory action is needed.

Side Effects

Common effects of Ozurdex 0.7 mg may include temporary vision changes, eye discomfort, or increased intraocular pressure. These effects are generally mild and transient, but users should monitor their symptoms and consult a healthcare provider if they persist or worsen.

Precautions & Warnings

Ozurdex 0.7 mg should be handled with care, ensuring proper sterile techniques during administration. It is important to follow the prescribed guidelines and avoid self-administration. Patients with certain eye conditions or infections should discuss their medical history with a healthcare provider before use.

Avoid Interactions

Ozurdex 0.7 mg may interact with other medications, particularly those affecting intraocular pressure or immune response. It is advisable to inform your healthcare provider about all current medications, including over-the-counter drugs and supplements, to avoid potential interactions.

Frequently Asked Questions

Ozurdex 0.7 mg is used to treat inflammation in the eye and macular edema, providing localized and sustained anti-inflammatory action.

Ozurdex 0.7 mg is administered via intraocular injection by a healthcare professional, ensuring proper sterile techniques.

Common side effects may include temporary vision changes, eye discomfort, or increased intraocular pressure.

It is important to consult a healthcare provider before using Ozurdex 0.7 mg with other medications to avoid potential interactions.

Patients with certain eye conditions or infections should discuss their medical history with a healthcare provider before using Ozurdex 0.7 mg.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.